abstract |
The present invention relates to the field of oligonucleotide pharmacotherapy, in particular novel oligomeric compounds for enhancing the properties of oligonucleotides. SOLUTION: An oligomer compound having a length of 8 to 35 nucleotides, which comprises the following three regions: (i) a first region (region A) (ii) containing 7 to 26 consecutive nucleotides, for example, an internucleoside linking group For example, a second region (region B) (iii) conjugate moiety comprising 1 to 10 nucleotides covalently linked to the 5 'nucleotide or 3' nucleotide of the first region via, for example, a phosphodiester linkage, targeting A third region, comprising a moiety, a reactive group, or a blocking moiety, covalently linked to a second region. [Selected figure] Figure 3 |